Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $131.00 at Citigroup

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target dropped by investment analysts at Citigroup from $136.00 to $131.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price objective would indicate a potential upside of 45.83% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group cut their target price on shares of Rhythm Pharmaceuticals from $141.00 to $140.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. Telsey Advisory Group set a $143.00 target price on Rhythm Pharmaceuticals in a research note on Thursday, March 12th. UBS Group reaffirmed a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, December 17th. Needham & Company LLC dropped their price objective on Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Citizens Jmp reduced their target price on Rhythm Pharmaceuticals from $176.00 to $152.00 and set a “market outperform” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $131.75.

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM traded down $0.68 during trading hours on Tuesday, reaching $89.83. The company’s stock had a trading volume of 308,818 shares, compared to its average volume of 711,385. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of -28.86 and a beta of 2.06. The firm has a 50-day simple moving average of $100.00 and a 200-day simple moving average of $102.91. Rhythm Pharmaceuticals has a 1 year low of $45.90 and a 1 year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The firm had revenue of $57.25 million for the quarter, compared to analysts’ expectations of $56.16 million. During the same period last year, the firm earned ($0.72) earnings per share. The company’s revenue for the quarter was up 36.9% compared to the same quarter last year. Equities analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the transaction, the chief accounting officer directly owned 160 shares of the company’s stock, valued at $14,329.60. This represents a 97.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 27,267 shares of company stock worth $2,719,955. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Xponance LLC boosted its position in shares of Rhythm Pharmaceuticals by 2.6% during the fourth quarter. Xponance LLC now owns 4,269 shares of the company’s stock valued at $457,000 after buying an additional 107 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Rhythm Pharmaceuticals by 4.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock valued at $259,000 after acquiring an additional 110 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Rhythm Pharmaceuticals by 39.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 399 shares of the company’s stock valued at $43,000 after acquiring an additional 113 shares during the last quarter. Captrust Financial Advisors grew its stake in shares of Rhythm Pharmaceuticals by 0.7% in the second quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock worth $1,104,000 after acquiring an additional 114 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Rhythm Pharmaceuticals by 48.6% during the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after purchasing an additional 118 shares during the last quarter.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Company reported strong commercial momentum and an earnings beat: FY25 revenue grew ~50% to $194.8M driven by IMCIVREE (setmelanotide), and the Q4 results beat expectations — supporting upside ahead of the March 20 PDUFA for acquired hypothalamic obesity. FY25 revenue/PDUFA article
• Positive Sentiment: Major brokers cut price targets but kept positive ratings — signaling continued analyst conviction: Citizens Jmp to $152 (market outperform), BofA to $139 (buy), Morgan Stanley to $136 (overweight), Needham to $130 (buy); all still imply meaningful upside from current levels. Benzinga: analyst moves TickerReport: Needham note
• Neutral Sentiment: Company-hosted transcript and slide deck from the Phase 3 EMANATE topline presentation are available for review — useful for investors digging into subgroup and post‑hoc details. Seeking Alpha: transcript Seeking Alpha: slideshow
• Negative Sentiment: Topline EMANATE Phase 3: the program failed to meet pre‑specified primary endpoints in four substudies — a material clinical setback that is pressuring the stock and raising near‑term uncertainty around label expansion and commercial prospects. Reuters: trial fail
• Negative Sentiment: Company press release confirms four substudies did not meet endpoints, though post‑hoc analyses showed statistically significant BMI reductions in select heterozygous genotypes — this mixed readout keeps regulatory and commercial outcomes uncertain. GlobeNewswire: EMANATE topline

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.